Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Transplantation Direct|February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld StudyMichele Malagola, Nicola Polverelli, Massimo Martino, et al.
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Transplantation and Cellular Therapy|May 9, 2021
Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei TrapiantiAlessandra Picardi, Nicoletta Sacchi, Valeria Miotti, et al.
Bone Marrow Transplantation|April 13, 2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01Francesca Bonifazi, Chiara Pavoni, Jacopo Peccatori, et al.
Haematologica|April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patientsGregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 19, 2026
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry StudyMichele Malagola, Domenica Matranga, Luca Castagna, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation GroupDiana Averbuch, Gloria Tridello, Jennifer Hoek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2014
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Corrado Girmenia, Anna Maria Raiola, Alfonso Piciocchi, et al.
Pageof 16